Top-selling PBS drug expands

The TGA has approved a granule formulation of Vertex's Trikafta for children with cystic fibrosis (CF) as young as two years who have at least one F508del mutation in the CFTR gene.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here